• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新辅助西妥昔单抗治疗局部晚期唇部鳞状细胞癌获完全病理缓解

Neoadjuvant Cetuximab Leading to a Complete Pathologic Response in Locally Advanced Lip Squamous Cell Carcinoma.

作者信息

Alchaikh Hassan Ruba, Gafarzadeh Zahra, Salmasi Shiva, Hyams David M, Dasanu Constantin A

机构信息

Internal Medicine, Eisenhower Health, Rancho Mirage, USA.

Internal Medicine, Eisenhower Medical Center, Rancho Mirage, USA.

出版信息

Cureus. 2024 Dec 2;16(12):e75000. doi: 10.7759/cureus.75000. eCollection 2024 Dec.

DOI:10.7759/cureus.75000
PMID:39749049
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11693926/
Abstract

Vermillion lip squamous cell carcinoma (SCC) is a rare cancer, currently grouped together with the cutaneous lip under the cutaneous squamous cell carcinoma (cSCC) system. Herein, we present a case of an 81-year-old male with locally advanced lower lip SCC involving the vermillion who achieved a complete pathologic response to neoadjuvant cetuximab after the failure of the programed cell death protein-1 (PD-1) inhibitor, cemiplimab. He was followed with clinical observation, with special attention to skin/mucosal surfaces. At the 24-week follow-up visit, he had no signs of recurrence and was very content with the surgical and cosmetic outcome. To our knowledge, there have been no documented cases of successful use of cetuximab as a neoadjuvant treatment for cSCC of the vermilion lip to date. This case highlights the potential role of cetuximab in this setting, where we believe clinical trials are warranted.

摘要

唇红部鳞状细胞癌（SCC）是一种罕见的癌症，目前在皮肤鳞状细胞癌（cSCC）系统中与唇部皮肤癌归为一类。在此，我们报告一例81岁男性患者，其下唇唇红部局部晚期SCC，在程序性细胞死亡蛋白1（PD - 1）抑制剂西米普利单抗治疗失败后，新辅助使用西妥昔单抗获得了完全病理缓解。对其进行临床观察，特别关注皮肤/黏膜表面。在24周的随访中，他没有复发迹象，对手术和美容效果非常满意。据我们所知，迄今为止尚无西妥昔单抗成功用于唇红部cSCC新辅助治疗的文献记载病例。该病例突出了西妥昔单抗在此种情况下的潜在作用，我们认为有必要开展临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db22/11693926/d58f37f5cb9c/cureus-0016-00000075000-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db22/11693926/31ceec071629/cureus-0016-00000075000-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db22/11693926/521af6491a03/cureus-0016-00000075000-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db22/11693926/53e0f7a05d64/cureus-0016-00000075000-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db22/11693926/d58f37f5cb9c/cureus-0016-00000075000-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db22/11693926/31ceec071629/cureus-0016-00000075000-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db22/11693926/521af6491a03/cureus-0016-00000075000-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db22/11693926/53e0f7a05d64/cureus-0016-00000075000-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db22/11693926/d58f37f5cb9c/cureus-0016-00000075000-i04.jpg

相似文献

1
Neoadjuvant Cetuximab Leading to a Complete Pathologic Response in Locally Advanced Lip Squamous Cell Carcinoma.新辅助西妥昔单抗治疗局部晚期唇部鳞状细胞癌获完全病理缓解
Cureus. 2024 Dec 2;16(12):e75000. doi: 10.7759/cureus.75000. eCollection 2024 Dec.
2
Use of Preoperative Immunotherapy in Locally Advanced Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report.术前免疫疗法在局部晚期不可切除皮肤鳞状细胞癌中的应用：一例报告
Case Rep Oncol. 2024 Oct 3;17(1):1109-1114. doi: 10.1159/000540842. eCollection 2024 Jan-Dec.
3
Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.晚期皮肤鳞状细胞癌对免疫疗法的反应：病例报告
Stem Cell Investig. 2021 Sep 6;8:19. doi: 10.21037/sci-2020-071. eCollection 2021.
4
Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.新辅助意向免疫治疗晚期可切除皮肤鳞状细胞癌。
JAMA Otolaryngol Head Neck Surg. 2024 May 1;150(5):414-420. doi: 10.1001/jamaoto.2024.0259.
5
Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.西妥昔单抗作为辅助或新辅助治疗在治疗皮肤鳞状细胞癌中的疗效。
Ann Plast Surg. 2024 Apr 1;92(4S Suppl 2):S129-S131. doi: 10.1097/SAP.0000000000003847.
6
Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.西妥昔单抗治疗局部晚期皮肤鳞状细胞癌 3 例独特病例系列
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221121408. doi: 10.1177/23247096221121408.
7
Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.病例报告：接受西米普利单抗治疗的多灶性局部晚期皮肤鳞状细胞癌患者并发自身免疫性寻常型天疱疮
Front Oncol. 2021 Aug 23;11:691980. doi: 10.3389/fonc.2021.691980. eCollection 2021.
8
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.西妥昔单抗在局部晚期和转移性皮肤鳞状细胞癌中的真实世界数据。
Eur J Cancer. 2021 Nov;157:250-258. doi: 10.1016/j.ejca.2021.08.018. Epub 2021 Sep 15.
9
Pseudoprogression of cutaneous squamous cell carcinoma invading the super vermillion border following programmed death-1 inhibitor monotherapy.程序性死亡-1抑制剂单药治疗后侵犯上唇红缘的皮肤鳞状细胞癌假性进展
Skin Health Dis. 2024 May 30;4(4):e400. doi: 10.1002/ski2.400. eCollection 2024 Aug.
10
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.新辅助西妥昔单抗联合手术治疗 II-IV 期皮肤鳞状细胞癌：一项单臂、多中心、Ⅱ期研究的随访和生存结果。
Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21.

本文引用的文献

1
Neoadjuvant Approaches to Non-Melanoma Skin Cancer.非黑色素瘤皮肤癌的新辅助治疗方法
Cancers (Basel). 2023 Nov 21;15(23):5494. doi: 10.3390/cancers15235494.
2
Treatment outcomes of squamous cell carcinoma of the lip: A retrospective study.唇鳞状细胞癌的治疗结果：一项回顾性研究。
Oncol Lett. 2022 Nov 14;25(1):8. doi: 10.3892/ol.2022.13594. eCollection 2023 Jan.
3
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.新辅助西妥昔单抗治疗 II 期至 IV 期皮肤鳞状细胞癌。
N Engl J Med. 2022 Oct 27;387(17):1557-1568. doi: 10.1056/NEJMoa2209813. Epub 2022 Sep 12.
4
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.头颈部局部晚期可切除皮肤鳞状细胞癌新辅助免疫治疗的 II 期临床试验。
Clin Cancer Res. 2021 Aug 15;27(16):4557-4565. doi: 10.1158/1078-0432.CCR-21-0585. Epub 2021 Jun 29.
5
Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma.非黑色素瘤皮肤癌的新辅助治疗：基底细胞癌、鳞状细胞癌和 Merkel 细胞癌的更新治疗方法。
Curr Treat Options Oncol. 2021 Mar 16;22(4):35. doi: 10.1007/s11864-021-00826-3.
6
Dermoscopic Features of Lower Lip Squamous Cell Carcinoma: A Descriptive Study.下唇鳞状细胞癌的皮肤镜特征：一项描述性研究。
Indian Dermatol Online J. 2019 Aug 28;10(5):536-541. doi: 10.4103/idoj.IDOJ_435_18. eCollection 2019 Sep-Oct.
7
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.含西妥昔单抗的联合方案用于局部晚期及复发或转移性头颈部鳞状细胞癌
Front Oncol. 2019 May 20;9:383. doi: 10.3389/fonc.2019.00383. eCollection 2019.
8
Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of Head and Neck Cancer: Rationale and Implications.第 8 版美国癌症联合委员会（AJCC）头颈部癌症分期的变化：原理与意义。
Curr Oncol Rep. 2019 Apr 17;21(6):52. doi: 10.1007/s11912-019-0799-x.
9
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.放疗联合西妥昔单抗或顺铂治疗人乳头瘤病毒阳性口咽癌（NRG 肿瘤学 RTOG 1016）：一项随机、多中心、非劣效性试验。
Lancet. 2019 Jan 5;393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15.
10
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.放疗联合顺铂或西妥昔单抗治疗低危型人乳头瘤病毒阳性口咽癌（De-ESCALaTE HPV）：一项开放标签随机对照 3 期临床试验。
Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15.